Rezolute rises as FDA lifts partial clinical hold on blood sugar treatment

Rezolute

09/09/2024 13:38

** Shares of drug developer Rezolute  RZLT.O  rise 13.3% to
$4.93 premarket
    ** U.S. FDA removes partial clinical holds on drug RZ358,
also known as ersodetug - RZLT
    ** Drug being studied as a treatment for low blood sugar
caused by genetic disorder called congenital hyperinsulinism
    ** Co will now start preparation for including U.S.
participants in late-stage trial
    ** RZLT expects U.S. enrollment to begin in early 2025 and
data in H2 2025
    ** Congenital hyperinsulinism is a rare disease in which
beta cells of pancreas secrete too much insulin
    ** Co's stock up ~338% YTD as of last close

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com))